GlassScriptPhysician profile
Michael Sizemore
NPI 1184335762
$3,873.63
in general payments reported to CMS, 2019-2025
22 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $641 · 2024: $1,010 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,802 · Education: $71.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,802.41 |
| Education | $71.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.43 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.58 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $503.86 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $322.67 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $264.67 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $221.87 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $216.73 | 2023-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $193.00 | 2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $181.79 | 2023-2025 | Spravato |
| Lundbeck LLC | $129.12 | 2023-2025 | Rexulti |
| Luye Pharma (USA) LTD. | $56.98 | 2025 | Erzofri Extended-Release |
| Novo Nordisk INC | $35.46 | 2025 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $30.97 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $29.25 | 2025 | Trintellix |
| Boston Scientific Corporation | $20.62 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $20.08 | 2024 | Perseris |
| Tris Pharma INC | $16.74 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $15.50 | 2025 | Cobenfy |
| Exact Sciences Corporation | $15.46 | 2024 | Cologuard Collection Kit |
| Watermark Medical, INC. | $14.18 | 2024 | |
| Pfizer INC. | $13.42 | 2023 | |
| Corium, LLC | $12.25 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sizemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.